<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->

<head>
	<meta charset="utf-8">
<meta name="author" content="Dove Press">
<meta name="viewport" content="initial-scale=1.0, width=device-width">
<title>IDH1 and IDH2 mutations as novel therapeutic targets: current perspect | JBM</title>
<meta property="og:title" content="IDH1 and IDH2 mutations as novel therapeutic targets: current perspect | JBM" />
<meta name="description" content="IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Johanna Mondesir,1,2 Christophe Willekens,3&acirc;€“5 Mehdi Touat,6,7 St&Atilde;&copy;phane de Botton,3&acirc;€“5 1Service d&acirc;€™Immunopathologie Clinique, H&Atilde;&acute;pital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Universit&Atilde;&copy; Paris Descartes, Paris, 3Gustave Roussy, Universit&Atilde;&copy; Paris-Saclay, Service d&acirc;€™H&Atilde;&copy;matologie Clinique, 4INSERM U1170, Gustave Roussy, Universit&Atilde;&copy; Paris-Saclay, Villejuif, 5Facult&Atilde;&copy; de m&Atilde;&copy;decine Paris-Sud, Kremlin-Bic&Atilde;&ordf;tre, 6AP-HP, H&Atilde;&acute;pitaux Universitaires La Piti&Atilde;&copy; Salp&Atilde;&ordf;tri&Atilde;&uml;re &acirc;€“ Charles Foix, Service de Neurologie 2-Mazarin, Paris, 7Gustave Roussy, Universit&Atilde;&copy; Paris&acirc;€‘Saclay, D&Atilde;&copy;partement d&acirc;€™Innovation Th&Atilde;&copy;rapeutique et d&acirc;€™Essais Pr&Atilde;&copy;coces, Villejuif, France Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to &Icirc;&plusmn;-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit &Icirc;&plusmn;-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection of&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients with&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;mutations and represent a novel drug class for targeted therapy. Keywords: tumor metabolism, epigenetic, oncogene, IDH1, IDH2, glioma, acute myeloid leukemia, 2-HG, targeted therapies" />
<meta property="og:description" content="IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Johanna Mondesir,1,2 Christophe Willekens,3&acirc;€“5 Mehdi Touat,6,7 St&Atilde;&copy;phane de Botton,3&acirc;€“5 1Service d&acirc;€™Immunopathologie Clinique, H&Atilde;&acute;pital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Universit&Atilde;&copy; Paris Descartes, Paris, 3Gustave Roussy, Universit&Atilde;&copy; Paris-Saclay, Service d&acirc;€™H&Atilde;&copy;matologie Clinique, 4INSERM U1170, Gustave Roussy, Universit&Atilde;&copy; Paris-Saclay, Villejuif, 5Facult&Atilde;&copy; de m&Atilde;&copy;decine Paris-Sud, Kremlin-Bic&Atilde;&ordf;tre, 6AP-HP, H&Atilde;&acute;pitaux Universitaires La Piti&Atilde;&copy; Salp&Atilde;&ordf;tri&Atilde;&uml;re &acirc;€“ Charles Foix, Service de Neurologie 2-Mazarin, Paris, 7Gustave Roussy, Universit&Atilde;&copy; Paris&acirc;€‘Saclay, D&Atilde;&copy;partement d&acirc;€™Innovation Th&Atilde;&copy;rapeutique et d&acirc;€™Essais Pr&Atilde;&copy;coces, Villejuif, France Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to &Icirc;&plusmn;-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit &Icirc;&plusmn;-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection of&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients with&Acirc;&nbsp;IDH1/2&Acirc;&nbsp;mutations and represent a novel drug class for targeted therapy. Keywords: tumor metabolism, epigenetic, oncogene, IDH1, IDH2, glioma, acute myeloid leukemia, 2-HG, targeted therapies" />
<meta property="og:image" content="https://www.dovepress.com/assets/img/addon/og_logo.png" />
<meta property="og:type" content="website" />
<link rel="canonical" href="https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" />
<meta property="og:url" content="https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" />
<link itemprop="sameAs" href="https://twitter.com/dovepress">
<link rel="image_src" href="assets/img/addon/favicon.ico" />
<link rel="shortcut icon" type="image/x-icon" href="assets/img/addon/favicon.ico" />
<meta name="citation_title" content="IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives">
<meta name="citation_publication_date" content="2016/09/02">
<meta name="citation_journal_title" content="Journal of Blood Medicine">
<meta name="citation_journal_issn" content="1179-2736">
<meta name="citation_journal_abbrev" content="JBM">
<meta name="citation_publisher" content="Dove Press">
<meta name="citation_language" content="English">
<meta name="citation_volume" content="7">
<meta name="citation_firstpage" content="171">
<meta name="citation_lastpage" content="180">
<meta name="citation_doi" content="10.2147/JBM.S70716">
<meta name="citation_pdf_url" content="https://www.dovepress.com/getfile.php?fileID=32220">
<meta name="citation_author" content="Johanna Mondesir">
<meta name="citation_author" content="Christophe Willekens">
<meta name="citation_author" content="Mehdi Touat">
<meta name="citation_author" content="StÃ©phane de Botton">
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.css"  media="all" />
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.articles.print.css"  media="print" />
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.articles.screen.css"  media="screen" />
<!--[if lt IE 9]>
<script src="assets/js/html5shiv.js"></script>
<![endif]-->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-W2V6CH');</script>
<!-- End Google Tag Manager -->

</head>
<body>
    <!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W2V6CH"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->    <div id="modal_wrapper">
        <div id="modal_bg"></div>
        <div id="modal_popup"></div>
    </div>
	<noscript>
	<div id='jswarn'>
	<p>Javascript is currently disabled in your browser. Several features of
	this site will not function whilst javascript is disabled.</p>
	</div>
</noscript>
	<div id="page">
        <div id="mobile-bg">
	<div class="mobile">
		<ul>
			<li><a href="browse_journals.php" id="browse-journals">Browse Journals</a></li>
			<li><a href="why_publish_with_dove.php" id="why-publish">Why Publish With Dove?</a></li>
			<li><a href="editors_in_chief.php" id="editors-in-chief">Editors-in-Chief</a></li>
			<li><a href="author_guidelines.php" id="author-guidelines">Author Guidelines</a></li>
			<li><a href="peer_review_guidelines.php" id="peer-review-guidelines">Peer Review Guidelines</a></li>
			<li><a href="open_outlook.php" id="open-outlook">Open Outlook</a></li>
			<li><a href="blog_post.php" id="blog-post">Blog</a></li>
			<li><a href="#" id="submit-manuscript" class="orange">Submit Manuscript</a></li>
		</ul>
	</div>
</div>
<div class="top_bg group">
	<div class="top group">
		<div class="mobile-nav">
			<a href="#" id="toggle"><img src="assets/img/mobile-icon.png" width="20" height="14" /> Menu</a>
		</div>
		<ul>
			<li><a href="about_dovepress.php">About</a></li>
			<li class="mobile-top"><a href="contact.php" class="contact">Contact</a></li>
			<li><a href="sustainability.php">Sustainability</a></li>
			<li><a href="press_releases.php">Press Releases</a></li>
			<li><a href="testimonials.php">Testimonials</a></li>
			<li><a href="blog_post.php">Blog</a></li>
			<li><a href="fav_author.php">Favored Author Program</a></li>
			<li><a href="permissions.php">Permissions</a></li>
			<li><a href="presubmission_check.php">Pre-Submission</a></li>
			<li class="mobile-top">
									<a href="login.php" class="login"><strong>Login</strong></a>
								</li>
            <li class="mobile-top">
                <a target="_blank" href="http://www.dovepress.com.cn"><img src="assets/img/flags/cn-2.png" alt="Chinese website (ä¸­æ–‡ç½‘ç«™)" title="Chinese website (ä¸­æ–‡ç½‘ç«™)" /></a>
            </li>
		</ul>
	</div>
</div>

<div class="mast_bg group">
	<div class="mast group">
		<div class="logo">
			<a href="index.php" name="page-top"><img src="assets/img/logo.png" width="205" height="43" /></a>
			<p>open access to scientific and medical research</p>	
		</div>
		<!-- /end logo -->
		<div class="search-bg">
			<form method="get" action="search_results.php">
				<input type="text" name="search_word" value="" placeholder="Search Dove Press" class="search" />
				<span style="display: inline-block">
					<input type="submit" value="Search" class="btn-search" id="sitewide-search" />
					<a href="search_advance.php" class="link-search-advanced">Advanced search</a>
				</span>
			</form>
		</div>
		<!-- /end search_bg -->
        	</div>
	<!-- /end mast -->
</div>
<!-- /end mast_bg -->


<nav role="navigation" class="nav_bg group">
	<div class="nav group">
		<ul>
			<li class=""><a href="index.php" >Home</a></li><li class=""><a href="browse_journals.php" >Browse Journals</a></li><li class=""><a href="why_publish_with_dove.php" >Why Dove?</a></li><li class=""><a href="editors_in_chief.php" >Editors-in-Chief</a></li><li class=""><a href="author_guidelines.php" >Author Guidelines</a></li><li class=""><a href="peer_review_guidelines.php" >Peer Review Guidelines</a></li><li class=""><a href="open_outlook.php" >Open Outlook</a></li>		</ul>
	</div>
	<!-- /end nav -->
</nav>
<!-- /end nav_bg -->		<div class="grid_bg group">
			<div class="grid group">
				<aside role="complementary" class="sidebar">
					<section class="box-wrap"><section class="box-ticker"><div class="small-bottom-padding"><h5>Average Article Statistics</h5></div><div class="no-top-padding">
								<div class="journal-counter">
									<h4><span class="ticker-num">1</span><span class="ticker-num">6</span> <span class="ticker-days">Days</span></h4>
								</div>
								<div class="box-ticker-note">*</div>
								<p class="journal-ticker">from submission to first editorial decision.</p>
							</div><div class="no-top-padding">
								<div class="journal-counter">
									<h4><span class="ticker-num">4</span><span class="ticker-num">5</span> <span class="ticker-days">Days</span></h4>
								</div>
								<div class="box-ticker-note">*</div>
								<p class="journal-ticker">from editorial acceptance to publication.</p>
							</div><div class="no-top-padding box-ticker-footnote"><p>*Business days (Mon-Fri)</p></div></section></section><section class="box-wrap">
	<section class="box-ticker">
		<div class="padding">
			<div class="ticker">
				<h4>
					<span class="ticker-num">3</span><span class="ticker-num">3</span><span class="ticker-num">2</span><span class="ticker-num">4</span><span class="ticker-num">6</span>				</h4>
			</div>
			<p>Papers Published</p>
		</div>
	</section>
</section>
<section class="box-wrap">
	<section class="box-none">
		<div class="width-padding">
		<a href="submit_step_1.php" class="manuscript-btn">Submit Manuscript</a>
		</div>
	</section>
	<!-- /end box -->
</section>
<!-- /end box-wrap --><section class="box-wrap">
	<section class="box light-green">
		<div class="padding">
			<h4>Journal Email Alerts</h4>
			<a href="register.php" class="alerts-btn">Signup for Alerts</a>
		</div>
	</section>
	<!-- /end box -->
</section>
<!-- /end box-wrap -->			<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>About Dove Press</h4>
												<p>Open access peer-reviewed scientific and medical journals.</p>
													<a href="http://www.dovepress.com/about_dovepress.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>Open Access</h4>
													<img src="cr_data/promo_box_image/promo_9.jpg" />
													<p>Dove Medical Press is a member of the OAI.</p>
													<a href="why_publish_with_dove.php?content_id=3045"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>Reprints</h4>
												<p>Bulk reprints for the pharmaceutical industry.</p>
													<a href="bulk_reprints.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap promo-box">
				<section class="box-open">
					<div class="padding">
						<h4>Favored Authors</h4>
												<p>We offer real benefits to our authors, including fast-track processing of papers.</p>
													<a href="fav_author.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
			<!-- end echoFromCache --><section class="box-wrap">
	<section class="box-open">
		<div class="padding">
			<h5>Social Media</h5>
			<a href="https://www.facebook.com/DoveMedicalPress" class="btn-facebook" id="facebook"></a> &nbsp;
			<a href="https://twitter.com/DovePress" class="btn-twitter" id="twitter"></a> &nbsp;
			<a href="https://www.linkedin.com/company/dove-medical-press" class="btn-linked-in" id="linked-in"></a> &nbsp;
			<a href="https://plus.google.com/103430773410928392958" class="btn-google" id="google"></a> &nbsp;
			<a href="https://www.youtube.com/user/dovepress" class="btn-youtube" id="youtube"></a>
		</div>
	</section>
	<!-- /end box-open -->
</section>
<!-- /end box-wrap --><section class="box-wrap">
	<section class="box-none">
        <iframe src="live_chat.php" width="90%" height="60"></iframe>
	</section>
	<!-- /end box-open -->
</section>
<!-- /end box-wrap -->				</aside>
	
				<div role="main" class="main" id="content">
					<p class="back">Back to <a href="browse_journals.php">Browse Journals</a> &raquo; <a href="journal-of-blood-medicine-journal">Journal of Blood Medicine</a> &raquo; <a href="journal-of-blood-medicine-archive85-v1073">Volume 7</a></p><div class="tabs-bg group"><div class="tabs-padding group">	<div class="article-labels group">
        <div class="tag  article-tag">Review</div>	</div>
	<h1>IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives</h1><div class="mobile-social"><a href="https://twitter.com/intent/tweet?text=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM+%40DovePress&related=DovePress&url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-twitter btn-page-share" id="twitter" title="share this page on Twitter"></a>&nbsp;<a href="https://www.facebook.com/sharer.php?u=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&t=IDH1 and IDH2 mutations as novel therapeutic targets: current perspect | JBM" class="btn-facebook btn-page-share" id="facebook" title="share this page on Facebook"></a>&nbsp;<a href="qr.php?p=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-wechat btn-page-share" id="wechat" title="share this page on WeChat"></a>&nbsp;<a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&title=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM&source=Dove Press" class="btn-linked-in btn-page-share" title="share this page on Linkedin"></a>&nbsp;<a href="http://del.icio.us/post?url= https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-delicious btn-page-share" id="delicious" title="share this page on Delicious"></a>&nbsp;<a href="https://plus.google.com/share?url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-google btn-page-share" id="google" title="share this page on Google+"></a>&nbsp;<a href="https://www.reddit.com/submit?url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-reddit btn-page-share" id="reddit" title="share this page on Reddit"></a>&nbsp;<a href="http://www.citeulike.org/posturl?url=https%3A%2F%2Fwww.dovepress.com%2Fidh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&title=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM" class="btn-citeulike" id="citeulike" title="share this page on CiteULike"></a>&nbsp;<a href="http://www.mendeley.com/import/?url=https%3A%2F%2Fwww.dovepress.com%2Fidh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-mendeley" id="mendeley" title="share this page on Mendeley"></a>&nbsp;<a href="site_referral.php?article_id=28724" class="btn-email" id="email" title="share this page via Email"></a>&nbsp;</div><div class="tabs print-hide"><a href="https://twitter.com/intent/tweet?text=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM+%40DovePress&related=DovePress&url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-twitter btn-page-share" id="twitter" title="share this page on Twitter"></a>&nbsp;<a href="https://www.facebook.com/sharer.php?u=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&t=IDH1 and IDH2 mutations as novel therapeutic targets: current perspect | JBM" class="btn-facebook btn-page-share" id="facebook" title="share this page on Facebook"></a>&nbsp;<a href="qr.php?p=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-wechat btn-page-share" id="wechat" title="share this page on WeChat"></a>&nbsp;<a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&title=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM&source=Dove Press" class="btn-linked-in btn-page-share" title="share this page on Linkedin"></a>&nbsp;<a href="http://del.icio.us/post?url= https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-delicious btn-page-share" id="delicious" title="share this page on Delicious"></a>&nbsp;<a href="https://plus.google.com/share?url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-google btn-page-share" id="google" title="share this page on Google+"></a>&nbsp;<a href="https://www.reddit.com/submit?url=https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-reddit btn-page-share" id="reddit" title="share this page on Reddit"></a>&nbsp;<a href="http://www.citeulike.org/posturl?url=https%3A%2F%2Fwww.dovepress.com%2Fidh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM&title=IDH1+and+IDH2+mutations+as+novel+therapeutic+targets%3A+current+perspect+%7C+JBM" class="btn-citeulike" id="citeulike" title="share this page on CiteULike"></a>&nbsp;<a href="http://www.mendeley.com/import/?url=https%3A%2F%2Fwww.dovepress.com%2Fidh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM" class="btn-mendeley" id="mendeley" title="share this page on Mendeley"></a>&nbsp;<a href="site_referral.php?article_id=28724" class="btn-email" id="email" title="share this page via Email"></a>&nbsp;<ul><li class="here"><a href="#"  >Abstract</a></li><li class=""><a href="idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-fulltext-article-JBM"  title="Machine readable">Fulltext</a></li><li class=""><a href="article_metric.php?article_id=28724"  >Metrics</a></li><li class=""><a href="//www.copyright.com/ccc/openurl.do?&issn=1179-2736&WT.mc.id=Dove Medical Press" target="_blank" >Get Permission</a></li></ul></div><div class="tab-content">
	<div class="articles">
		
<div class="intro">
    <div class="padding">				
        <p>
            <strong>Authors</strong> Mondesir J, Willekens C, Touat M, de Botton S        </p>
                    <p>
                <strong>Received</strong> <abbr title="These are actual dates the paper was submitted to, accepted for, and published in the journal.">15 March 2016</abbr>
            </p>
            <p>
                <strong>Accepted for publication</strong> 31 May 2016            </p>
                    <p>
            <strong>Published</strong> 2 September 2016
                            <a href="journal-of-blood-medicine-archive85-v1073">Volume 2016:7</a>
                                Pages 171&mdash;180                        </p>

                    <p>
                <strong>DOI</strong> <a href="https://doi.org/10.2147/JBM.S70716">https://doi.org/10.2147/JBM.S70716</a>
            </p>
                        <p>
                <strong>Checked for plagiarism</strong> Yes
            </p>
                        <p>
                <strong>Review by</strong> <a href="peer_review_guidelines.php">Single-blind</a>
            </p>
                            <p>
                    <strong>Peer reviewers approved by</strong> <a target="_blank" href="public_profile.php?id=601075">Dr Colin Mak</a>
                </p>
                            <p>
                <strong>Peer reviewer comments</strong> 3            </p>
                        <p>
                <strong>Editor who approved publication: </strong>
                                    <a target="_blank" href="public_profile.php?id=32033">Dr Martin H. Bluth</a>
                    
            </p>
                        <div class='altmetric-embed' data-doi='https://doi.org/10.2147/JBM.S70716'></div>
                </div>
    <!-- /end padding -->
</div>
<!-- /end intro -->		
		<div class="copy">
			<p>Johanna Mondesir<sup>1,2</sup> Christophe Willekens<sup>3&ndash;5</sup> Mehdi Touat<sup>6,7</sup> St&eacute;phane de Botton<sup>3&ndash;5</sup><br /><br /><sup> 1</sup>Service d&rsquo;Immunopathologie Clinique, H&ocirc;pital Saint Louis, <sup>2</sup>CNRS UMR8104, INSERM U1016, Institut Cochin, Universit&eacute; Paris Descartes, Paris, <sup>3</sup>Gustave Roussy, Universit&eacute; Paris-Saclay, Service d&rsquo;H&eacute;matologie Clinique, <sup>4</sup>INSERM U1170, Gustave Roussy, Universit&eacute; Paris-Saclay, Villejuif, <sup>5</sup>Facult&eacute; de m&eacute;decine Paris-Sud, Kremlin-Bic&ecirc;tre, <sup>6</sup>AP-HP, H&ocirc;pitaux Universitaires La Piti&eacute; Salp&ecirc;tri&egrave;re &ndash; Charles Foix, Service de Neurologie 2-Mazarin, Paris, <sup>7</sup>Gustave Roussy, Universit&eacute; Parisâ€‘Saclay, D&eacute;partement d&rsquo;Innovation Th&eacute;rapeutique et d&rsquo;Essais Pr&eacute;coces, Villejuif, France<br /><br /><strong> Abstract:</strong> Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to &alpha;-ketoglutarate. <em>IDH1/2</em> mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in&nbsp;<em>IDH1/2</em>&nbsp;confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit &alpha;-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection of&nbsp;<em>IDH1/2</em>&nbsp;mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients with&nbsp;<em>IDH1/2</em>&nbsp;mutations and represent a novel drug class for targeted therapy.<br /><br /><strong> Keywords:</strong> tumor metabolism, epigenetic, oncogene, IDH1, IDH2, glioma, acute myeloid leukemia, 2-HG, targeted therapies</p>				<p class="article-cc-license">
					<img alt="Creative Commons License" style="border-width:0" src="//i.creativecommons.org/l/by-nc/3.0/us/88x31.png" />
					This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <a target="_blank"  href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</a> and incorporate the <a target="_blank" rel="license" href="//creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution - Non Commercial (unported, v3.0) License</a>.

					By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of <a target="_blank"  xmlns:cc="//creativecommons.org/ns#" href="https://www.dovepress.com/terms.php" rel="cc:morePermissions">our Terms</a>.
				</p>
				<a class="download-btn print-hide" href="getfile.php?fileID=32220" id="download-pdf">Download Article <span>[PDF]</span></a>&nbsp;				<a class="download-btn print-hide" href="idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-fulltext-article-JBM" id="view-full-text">View Full Text <span>[HTML]</span><span class="text_machine">[Machine readable]</span></a>
								<p>&nbsp;</p>
				<script src="//api.growkudos.com/widgets/article/10.2147/JBM.S70716"></script>
						</div>
		<!-- /end copy -->
	</div>
	<!-- /end articles -->
</div>
<!-- /end tab-content -->
</div></div>				</div>
				<!-- /end main -->
			</div>
			<!-- /end grid -->
		</div>
		<!-- /end grid_bg -->
	
		<div class="footer-nav-bg group">
	<div class="footer-nav group">
		<div class="footer-desktop-nav">
			<p>
				<a href="contact.php">Contact Us</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="privacy.php">Privacy Policy</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="partners.php">Associations &amp; Partners</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="testimonials.php">Testimonials</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="sitemap.php">Sitemap</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="terms.php">Terms &amp; Conditions</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="site_referral.php">Recommend this site</a>
				<span>&bull;</span>&nbsp; <a href="#page-top">Top</a>
			</p>
		</div>
		<div class="footer-mobile-nav">
			<p><a href="contact.php">Contact Us</a> &nbsp;<span>&bull;</span>&nbsp; <a href="privacy.php">Privacy Policy</a></p>
		</div>
	</div>
	<!-- /end footer-nav -->
</div>
<!-- /end footer-nav-bg --><footer role="contentinfo" class="footer_bg group">
	<div class="footer group">
		<p>
			<strong>&copy; Copyright 2017</strong> &nbsp;<span>&bull;</span>&nbsp; <strong>Dove Press Ltd</strong> &nbsp;
							<span>&bull;</span>&nbsp; Website development by maffey.com
							<span>&bull;</span>&nbsp; Web Design by <a href="http://www.adhesion.co.nz" title="Adhesion Website Design">Adhesion</a>
		</p>
		<p class="small">The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.</p>
	</div>
	<!-- /end footer -->
	<br clear="all" />
</footer>
<!-- /end footer_bg -->	</div>
	<!-- /end #page -->
	
	<script type='text/javascript' src='assets/js/jquery-1.10.2.min.js'></script>
<script type='text/javascript' src='assets/js/jquery-ui-1.10.4.custom.min.js'></script>
<script type='text/javascript' src='assets/js/addon/jquery.formtools.js'></script>
<script type='text/javascript' src='assets/js/addon/jquery.popupBox.min.js'></script>
<script type='text/javascript' src='assets/js/jquery.news_ticker.min.js'></script>
<script type='text/javascript' src='assets/js/jquery.fitvids.js'></script>

<span id='javascript-insert-point'></span>

<script type='text/javascript'>
function addJS(url){
	var insertPoint = document.getElementById('javascript-insert-point');
	var element = document.createElement('script');
	element.src = url;
	insertPoint.appendChild(element);
}

function downloadJSAtOnload(){
	addJS('assets/js/main.js');
	addJS('assets/js/addon/addon_v2.js');
	addJS('assets/js/img-sizer.js');
	addJS('https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js');
}

if (window.addEventListener) {
	window.addEventListener('load', downloadJSAtOnload, false);
} else if (window.attachEvent) {
	window.attachEvent('onload', downloadJSAtOnload);
} else {
	window.onload = downloadJSAtOnload;
}

</script>
</body>
</html>